О.В. Ковалёва1, Д.Н. Кушлинский2, А.Н. Грачёв3, Е.П. Шапиро4, А.С. Мочалова5, Н.Ю. Соколов6, Н.Е. Кушлинский7

1,3,5–7 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Министерства здравоохранения Российской Федерации (Москва, Россия)

2,4 Краевой клинический центр онкологии (г. Хабаровск, Россия)

Постановка проблемы. Появление ингибиторов иммунных контрольных точек, в основном включающих моноклональные антитела к PD-1/PD-L1 и CTLA-4, сформировало терапевтический ландшафт некоторых видов злокачественных опухолей. Последние достижения в иммунотерапии демонстрируют хорошие результаты: наблюдаются увеличение общей выживаемости и частота объективных ответов у пациентов с различными типами опухолей. Однако в терапию рака яичников иммунотерапия не привнесла значительных успехов. Именно поэтому поиск и изучение новых контрольных точек иммунитета является крайне актуальным и перспективным.

Цель работы – анализ современных исследований, посвящённых белкам B7-H3 и B7-H4 и их роли в патогенезе опухолей яичников.

Результаты. Приведены данные о структуре и классификации белков семейства B7 (в частности, B7-H3 и B7-H4), их роли в адаптивном иммунном ответе, подавлении пролиферации, активации и продукции цитокинов, а также во взаимодействии с межклеточным матриксом. Рассмотрены многообразные функции данных белков как в норме, так и в развитии и прогрессии рака яичников.

Практическое значение. Оценка уровня экспрессии B7-H3 и B7-H4 может стать основой для разработки новых терапевтических и диагностических агентов, которые способны улучшить терапию опухолей яичников.

Ковалёва О.В., Кушлинский Д.Н., Грачёв А.Н., Шапиро Е.П., Мочалова А.С., Соколов Н.Ю., Кушлинский Н.Е. Рак яичников и лиганды B7-H3 и B7-H4 // Технологии живых систем. 2023. T. 20. № 3. С. 36-47. DOI: https://doi.org/10.18127/j20700997-202303-05

1. Antonia S.J., Extermann M., Flavell R.A. Immunologic nonresponsiveness to tumors // Crit. Rev. Oncog. 1998. V. 9. № 1. P. 35–41.
2. He C., Qiao H., Jiang H., Sun X. The inhibitory role of B7-H4 in antitumor immunity: association with cancer progression and survival // Clin. Dev. Immunol. 2011. P. 695834.
3. Igney F.H., Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack // J. Leukoc. Biol. 2002. V. 71. № 6. P. 907–920.
4. Scotta C., Soligo M., Camperio C., Piccolella E. FOXP3 induced by CD28/B7 interaction regulates CD25 and anergic phenotype in human CD4+CD25-T lymphocytes // J. Immunol. 2008. V. 181. № 2. P. 1025–1033.
5. Fridman W.H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates // Cancer Res. 2011. V. 71. № 17. P. 5601–5605.
6. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells // Nature. 2011. V. 475. № 7355. P. 226–230.
7. Fauci J.M., Straughn J.M. Jr., Ferrone S., Buchsbaum D.J. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer // Gynecol. Oncol. 2012. V. 127. № 2. P. 420–425.
8. Ye Q., Liu J., Xie K. B7 Family Proteins in Cancer Progression: Immunological and Non-Immunological Functions // J. Cancer Treat. Diagn. 2019. V. 3. № 4. P. 1–6.
9. Yao S., Zhu Y., Zhu G., Augustine M., Zheng L., Goode D.J., Broadwater M., Ruff W., Flies S., Xu H., Flies D., Luo L., Wang S., Chen L. B7-h2 is a costimulatory ligand for CD28 in human // Immunity. 2011. V. 34. № 5. P. 729–740.
10. Zhuang X., Long E.O. CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7(+) Tumor Cells // Cancer Immunol. Res. 2019. V. 7. № 6. P. 939–951.
11. Chapoval A.I., Ni J., Lau J.S., Wilcox R.A., Flies D.B., Liu D., Dong H., Sica G.L., Zhu G., Tamada K., Chen L. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production // Nat. Immunol. 2001. V. 2. № 3. P. 269–274.
12. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy // Nat. Rev. Cancer. 2012. V. 12. № 4. P. 252–264.
13. Tringler B., Zhuo S., Pilkington G., Torkko K.C., Singh M., Lucia M.S., Heinz D.E., Papkoff J., Shroyer K.R. B7-h4 is highly expressed in ductal and lobular breast cancer // Clin. Cancer Res. 2005. V. 11. № 5. P. 1842–1848.
14. Dangaj D., Lanitis E., Zhao A., Joshi S., Cheng Y., Sandaltzopoulos R., Ra H.J., Danet-Desnoyers G., Powell D.J. Jr., Scholler N. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses // Cancer Res. 2013. V. 73. № 15. P. 4820–4829.
15. Fan M., Zhuang Q., Chen Y., Ding T., Yao H., Chen L., He X., Xu X. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma // Int. J. Clin. Exp. Pathol. 2014. V. 7. № 10. P. 6768–6775.
16. Che F., Xie X., Wang L., Su Q., Jia F., Ye Y., Zang L., Wang J., Li H., Quan Y., You C., Yin J., Wang Z., Li G., Du Y., Wang L.
    B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas // Int. Immunopharmacol. 2018. V. 59. P. 318–327.
17. Fiegler N., Textor S., Arnold A., Rölle A., Oehme I., Breuhahn K., Moldenhauer G., Witzens-Harig M., Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells // Blood. 2013. V. 122. № 5. P. 684–693.
18. Hashiguchi M., Kobori H., Ritprajak P., Kamimura Y., Kozono H., Azuma M. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses // Proc. Natl. Acad. Sci. U S A. 2008. V. 105. № 30. P. 10495–10500.
19. Leitner J., Klauser C., Pickl W.F., Stockl J., Majdic O., Bardet A.F. et al. B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction // Eur. J. Immunol. 2009. V. 39. № 7. P. 1754–1764.
20. Suh W.K., Gajewska B.U., Okada H., Gronski M.A., Bertram E.M., Dawicki W., Duncan G.S., Bukczynski J., Plyte S., Elia A., Wakeham A., Itie A., Chung S., Da Costa J., Arya S., Horan T., Campbell P., Gaida K., Ohashi P.S., Watts T.H., Yoshinaga S.K., Bray M.R., Jordana M., Mak T.W. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses // Nat. Immunol. 2003. V. 4. № 9. P. 899–906.
21. Luo L., Chapoval A.I., Flies D.B., Zhu G., Hirano F., Wang S., Lau J.S., Dong H., Tamada K., Flies A.S., Liu Y., Chen L. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells // J. Immunol. 2004. V. 173. № 9. P. 5445–5450.
22. Fukushima A., Sumi T., Fukuda K., Kumagai N., Nishida T., Yamazaki T., Akiba H., Okumura K., Yagita H., Ueno H. B7-H3 regulates the development of experimental allergic conjunctivitis in mice // Immunol. Lett. 2007. V. 113. № 1. P. 52–57.
23. Nagashima O., Harada N., Usui Y., Yamazaki T., Yagita H., Okumura K., Takahashi K., Akiba H. B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma // J. Immunol. 2008. V. 181. № 6. P. 4062–4071.
24. Wu C.P., Jiang J.T., Tan M., Zhu Y.B., Ji M., Xu K.F., Zhao J.M., Zhang G.B., Zhang X.G. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis // World J. Gastroenterol. 2006. V. 12. № 3. P. 457–459.
25. Zang X., Thompson R.H., Al-Ahmadie H.A., Serio A.M., Reuter V.E., Eastham J.A., Scardino P.T., Sharma P., Allison J.P. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome // Proc. Natl. Acad. Sci. U S A. 2007. V. 104. № 49. P. 19458–19463.
26. Boorjian S.A., Sheinin Y., Crispen P.L., Farmer S.A., Lohse C.M., Kuntz S.M., Leibovich B.C., Kwon E.D., Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival // Clin. Cancer Res. 2008. V. 14. № 15. P. 4800–4808.
27. Crispen P.L., Sheinin Y., Roth T.J., Lohse C.M., Kuntz S.M., Frigola X., Thompson R.H., Boorjian S.A., Dong H., Leibovich B.C., Blute M.L., Kwon E.D. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma // Clin. Cancer Res. 2008. V. 14. № 16. P. 5150–5157.
28. Loos M., Hedderich D.M., Ottenhausen M., Giese N.A., Laschinger M., Esposito I., Kleeff J., Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer // BMC Cancer. 2009. V. 9. P. 463.
29. Jiang J., Zhu Y., Wu C., Shen Y., Wei W., Chen L., Zheng X., Sun J., Lu B., Zhang X. Tumor expression of B7–H4 predicts poor survival of patients suffering from gastric cancer // Cancer Immunol. Immunother. 2010. V. 59. № 11. P. 1707–1714.
30. Sun J., Chen L.J., Zhang G.B., Jiang J.T., Zhu M., Tan Y., Wang H.T., Lu B.F., Zhang X.G. Clinical significance and regulation of the costimulatory molecule B7–H3 in human colorectal carcinoma // Cancer Immunol. Immunother. 2010. V. 59. № 8. P. 1163–1171.
31. Zang X., Sullivan P.S., Soslow R.A., Waitz R., Reuter V.E., Wilton A., Thaler H.T., Arul M., Slovin S.F., Wei J., Spriggs D.R., Dupont J., Allison J.P. Tumor associated endothelial expression of B7–H3 predicts survival in ovarian carcinomas // Mod. Pathol. 2010. V. 23. № 8. P. 1104–1112.
32. Roth T.J., Sheinin Y., Lohse C.M., Kuntz S.M., Frigola X., Inman B.A., Krambeck A.E., McKenney M.E., Karnes R.J., Blute M.L., Cheville J.C., Sebo T.J., Kwon E.D. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy // Cancer Res. 2007. V. 67. № 16. P. 7893–7900.
33. Crispen P.L., Sheinin Y., Roth T.J., Lohse C.M., Kuntz S.M., Frigola X., Thompson R.H., Boorjian S.A., Dong H., Leibovich B.C., Blute M.L., Kwon E.D. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma // Clin. Cancer Res. 2008. V. 14. № 16. P. 5150–5157.
34. Gregorio A., Corrias M.V., Castriconi R., Dondero A., Mosconi M., Gambini C., Moretta A., Moretta L., Bottino C. Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule // Histopathology. 2008. V. 53. № 1. P. 73–80.
35. Yamato I., Sho M., Nomi T., Akahori T., Shimada K., Hotta K., Kanehiro H., Konishi N., Yagita H., Nakajima Y. Clinical importance of B7-H3 expression in human pancreatic cancer // Br. J. Cancer. 2009. V. 101. № 10. P. 1709–1716.
36. Xu H., Cheung I.Y., Guo H.F., Cheung N.K. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors // Cancer Res. 2009. V. 69. № 15. P. 6275–6281.
37. Chen Y.W., Tekle C., Fodstad O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion // Curr. Cancer Drug Targets. 2008. V. 8. № 5. P. 404–413.
38. Liu H., Tekle C., Chen Y.W., Kristian A., Zhao Y., Zhou M., Liu Z., Ding Y., Wang B., Mælandsmo G.M., Nesland J.M., Fodstad O., Tan M. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation // Mol. Cancer Ther. 2011. V. 10. № 6. P. 960–971.
39. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H., Chapoval A.I., Flies D.B., Bajorath J., Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity // Immunity. 2003. V. 18. № 6. P. 849–861.
40. Zang X., Loke P., Kim J., Murphy K., Waitz R., Allison J.P. B7x: a widely expressed B7 family member that inhibits T cell activation // Proc. Natl. Acad. Sci. U S A. 2003. V. 100. № 18. P. 10388–10392.
41. Choi I.H., Zhu G., Sica G.L., Strome S.E., Cheville J.C., Lau J.S., Zhu Y., Flies D.B., Tamada K., Chen L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family // J. Immunol. 2003. V. 171. № 9. P. 4650–4654.
42. Carreno B.M., Collins M. BTLA: a new inhibitory receptor with a B7-like ligand // Trends Immunol. 2003. V. 24. № 10. P. 524–527.
43. Prasad D.V., Richards S., Mai X.M., Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation // Immunity. 2003. V. 18. № 6. P. 863–873.
44. Salceda S., Tang T., Kmet M., Munteanu A., Ghosh M., Macina R., Liu W., Pilkington G., Papkoff J. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation // Exp. Cell Res. 2005. V. 306. № 1. P. 128–141.
45. Tringler B., Zhuo S., Pilkington G., Torkko K.C., Singh M., Lucia M.S., Heinz D.E., Papkoff J., Shroyer K.R. B7-h4 is highly expressed in ductal and lobular breast cancer // Clin. Cancer Res. 2005. V. 11. № 5. P. 1842–1848.
46. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., Leibovich B.C., Blute M.L., Cheville J.C., Kwon E.D. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival // Proc. Natl. Acad. Sci. U S A. 2006. V. 103. № 27. P. 10391–10396.
47. Jiang J., Zhu Y., Wu C., Shen Y., Wei W., Chen L., Zheng X., Sun J., Lu B., Zhang X. Tumor expression of B7–H4 predicts poor survival of patients suffering from gastric cancer // Cancer Immunol. Immunother. 2010. V. 59. № 11. P. 1707–1714.
48. Cheng L., Jiang J., Gao R., Wei S., Nan F., Li S., Kong B. B7-H4 expression promotes tumorigenesis in ovarian cancer // Int. J. Gynecol. Cancer. 2009. V. 19. № 9. P. 1481–1486.
49. Simon I., Katsaros D., Rigault de la Longrais I., Massobrio M., Scorilas A., Kim N.W., Sarno M.J., Wolfert R.L., Diamandis E.P. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression // Gynecol. Oncol. 2007. V. 106.
    № 2. P. 334–341.
50. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., Lackner A., Alvarez X., Ochoa A., Chen L., Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma // J. Exp. Med. 2006. V. 203. № 4. P. 871–881.
51. Zheng Y., Katsaros D., Shan S.J., de la Longrais I.R., Porpiglia M., Scorilas A., Kim N.W., Wolfert R.L., Simon I., Li L., Feng Z., Diamandis E.P. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy // Clin. Cancer Res. 2007. V. 13. № 23. P. 6984–6992.
52. Oikonomopoulou K., Li L., Zheng Y., Simon I., Wolfert R.L., Valik D., Nekulova M., Simickova M., Frgala T., Diamandis E.P. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel // Br. J. Cancer. 2008. V. 99. № 7. P. 1103–1113.